Elisabeth I. Heath, MD, FACP

Before centering discussion on subsets of prostate cancer, panelists consider general challenges and unmet needs within the treatment landscape.

Key opinion leaders provide a broad perspective on recent shifts in the treatment landscape for prostate cancer.

Medical oncologist Tian Zhang, MD, outlines the remaining unmet needs and knowledge gaps surrounding imaging of prostate cancer.

Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.

Closing out their review of the metastatic CRPC treatment paradigm, Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, look toward future evolutions in care.

Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, share perspective on the challenges inherent in delivering novel therapy to patients diagnosed with metastatic CRPC.

Comprehensive insight on factors that may influence the selection of cabazitaxel or radiotherapy for patients with metastatic castration-resistant prostate cancer.

A brief review of factors that may influence an academic or community physician’s choice to utilize cabazitaxel in the setting of metastatic castration-resistant prostate cancer.

Switching their focus to combination therapy in metastatic CRPC, expert oncologists review trial results from a study analyzing cabazitaxel/carboplatin therapy.

Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, review data from the CARD trial and discuss the nuanced selection and sequencing of treatment in metastatic CRPC.

Expert perspectives on the PROSELICA trial, which helped inform optimal dosing strategies with cabazitaxel in metastatic castration-resistant prostate cancer.

Centering discussion on the use of cabazitaxel in metastatic CRPC, key opinion leaders consider optimal sequencing of therapy in light of the TROPIC clinical trial.

Elisabeth I. Heath, MD, FACP, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).